Prime Medicine, Inc. (PRME)

Market Cap	704.61M
Revenue (ttm)	5.98M
Net Income (ttm)	-197.34M
Shares Out	177.04M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,691,862
Open	3.980
Previous Close	3.990
Day's Range	3.790 - 4.155
52-Week Range	1.110 - 6.940
Beta	2.72
Analysts	Buy
Price Target	6.42 (+61.31%)
Earnings Date	Feb 27, 2026

About PRME

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 20, 2022
• Employees: 214
• Stock Exchange: NASDAQ
• Ticker Symbol: PRME
• Website: https://primemedicine.com

Analyst Summary

According to 5 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $6.42, which is an increase of 61.31% from the latest price.

Price Target

$6.42

(61.31% upside)

Analyst Consensus: Buy